Subclinical Acute Antibody-Mediated Rejection in Positive Crossmatch Renal Allografts
Article first published online: 4 JAN 2007
American Journal of Transplantation
Volume 7, Issue 3, pages 576–585, March 2007
How to Cite
Haas, M., Montgomery, R. A., Segev, D. L., Rahman, M. H., Racusen, L. C., Bagnasco, S. M., Simpkins, C. E., Warren, D. S., Lepley, D., Zachary, A. A. and Kraus, E. S. (2007), Subclinical Acute Antibody-Mediated Rejection in Positive Crossmatch Renal Allografts. American Journal of Transplantation, 7: 576–585. doi: 10.1111/j.1600-6143.2006.01657.x
- Issue published online: 4 JAN 2007
- Article first published online: 4 JAN 2007
- Received 4 August 2006, revised 10 October 2006 and accepted for publication 28 October 2006
- chronic rejection;
- protocol biopsy;
- renal transplantation;
- transplant glomerulopathy
Subclinical antibody-mediated rejection (AMR) has been described in renal allograft recipients with stable serum creatinine (SCr), however whether this leads to development of chronic allograft nephropathy (CAN) remains unknown.
We retrospectively reviewed data from 83 patients who received HLA-incompatible renal allografts following desensitization to remove donor-specific antibodies (DSA). Ten patients had an allograft biopsy showing subclinical AMR [stable SCr, neutrophil margination in peritubular capillaries (PTC), diffuse PTC C4d, positive DSA] during the first year post-transplantation; 3 patients were treated with plasmapheresis and intravenous immunoglobulin. Three patients had a subsequent rise in SCr and an associated biopsy with AMR; 5 others showed diagnostic or possible subclinical AMR on a later protocol biopsy. One graft was lost, while remaining patients have normal or mildly elevatedSCr 8–45 months post-transplantation. However, the mean increase in CAN score (cg + ci + ct + cv) from those biopsies showing subclinical AMR to follow-up biopsies 335 ± 248 (SD) days later was significantly greater (3.5 ± 2.5 versus 1.0 ± 2.0, p = 0.01) than that in 24 recipients of HLA-incompatible grafts with no AMR over a similar interval (360 ± 117 days), suggesting that subclinical AMR may contribute to development of CAN.